Table 4. Adiponectin receptor 2 expression.
| Lean controls | Obese-pre | Obese-post | |
|---|---|---|---|
| Innate immunity | |||
| Monocytes (total) | 60 (32–67) | 68 (46–80) | 57 (43–70) |
| CD14++CD16- | 59 (29–66) | 60 (45–80) | 54 (41–67) |
| CD14++CD16+ | 79 (60–88) | 80 (67–93) | 75 (59–86) |
| CD14+CD16++ | 60 (44–70) | 63 (46–80) | 62 (44–68) |
| Natural Killer cells (CD16+CD56+) | 67 (62–80) # | 61 (53–72) | 62 (53–66) # |
| CD16+CD56++ | 98 (97–100) | 97 (95–99) | 98 (93–99) |
| CD16-CD56++ | 99 (96–100) | 97 (95–99) | 98 (97–100) |
| Bridging immunity | |||
| Natural Killer T cells | 77 (70–89) | 70 (61–74) | 77 (62–82) |
| Adaptive immunity | |||
| B cells | |||
| Naive (CD10-CD27-) | 38 (35–46) | 36 (32–41) | 35 (24–40) |
| Memory (CD10-CD27+) | 45 (39–52) | 43 (36–46) | 41 (19–47) |
| Immature transition (CD10+CD27+) | 74 (61–81) | 72 (58–87) | 77 (57–82) |
| CD4+ T helper cells | |||
| CD45RO- CXCR3- | 27 (25–32) # | 25 (20–38) | 25 (13–27) # |
| CD45RO- CXCR3+ | 54 (46–88) | 49 (40–58) | 50 (43–67) |
| CD45RO+ CXCR3- | 34 (31–39) | 32 (28–41) | 33 (14–37) |
| CD45RO+ CXCR3+ | 43 (36–62) | 40 (33–54) | 47 (33–60) |
| CD8+ cytotoxic T cells | |||
| CD45RO- CCR7- | 29 (11–34) | 31 (24–44) | 29 (12–33) |
| CD45RO- CCR7+ | 26 (22–48) | 24 (19–44) | 25 (20–38) |
| CD45RO+ CCR7- | 31 (13–41) | 36 (30–44) | 30 (7.6–35) |
| CD45RO+ CCR7+ | 58 (52–76) | 55 (35–80) | 58 (52–77) |
| Regulatory T cells (CD25+CD127-) | 23 (21–27) | 20 (15–27) | 22 (19–28) |
Percentage expression of adiponectin receptor 2 on leukocyte subsets of lean controls compared to obese children pre-lifestyle intervention (pre) and post-lifestyle intervention (post). Data are presented as median (interquartile range).
# p<0.05 for lean controls versus obese-post.